After years of failure, ViaCyte shows off first proof-of-concept for diabetes stem cell transplants
Seven years after they first tried it, ViaCyte finally has data showing that their stem cell treatment for diabetes — a potential cure — can work in a patient.
The data are extremely limited: They come from a single patient. But they provide, outside experts say, the first proof-of-concept for an approach that companies, including Vertex, and diabetes research foundations are betting could eventually provide a functional cure for many patients with type 1 diabetes and — down the road — the millions more with type 2 diabetes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.